Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

This is a Phase 2, randomized, multicenter, placebo-controlled study sponsored by BioMimetix
JV, LLC (BMX). It is a double-blind parallel cohort study designed to determine the safety
and efficacy of BMX-010 (0.03%) relative to Placebo in subjects with atopic dermatitis and
psoriasis.

Subjects will be queried regarding adverse events (AEs) and concomitant medication usage.

Inclusion Criteria:

- Diagnosis of either atopic dermatitis or psoriasis with mild to moderate lesions
involving 1% - 25% of total body surface area

- Candidate for topical treatment of atopic dermatitis or psoriasis

- Negative pregnancy test for females of childbearing potential

Exclusion Criteria:

- Systemic pharmacotherapy or phototherapy for treatment of atopic dermatitis or
psoriasis

- Erythrodermic, guttate or generalized pustular psoriasis

- Treatment of systemic retinoids, corticosteroids or immunosuppressive agents within 4
weeks of baseline visit

- Treatment with high potency topical steroids, vitamin D analogs, keratolytics, coal
tar, phototherapy, calcineurin inhibitors, or antihistamines within 2 weeks of
baseline visit

- UV or Dead Sea therapy within 4 weeks of baseline visit

- Treatment with a biologic agent (monoclonal antibody) within 30 days or 5 times its
circulating half-life (whichever is longer) prior to baseline visit

- Atopic dermatitis triggered by environmental allergen or irritant

- Contact dermatitis or drug-induced skin reactions

- Systemic or skin infection requiring antimicrobial therapy

- Systemic chemotherapy or radiotherapy within 4 weeks of baseline visit

- Immunocompromise of any cause

- Pregnancy, lactation or inadequate contraception

- Active drug or alcohol dependence

- Significant acute or chronic medical, neurological or psychiatric illness that would
compromise subject's safety